Autolus Therapeutics Ltd (AUTL)vsRegeneron Pharmaceuticals Inc (REGN)
AUTL
Autolus Therapeutics Ltd
$1.46
+0.69%
HEALTHCARE · Cap: $383.25M
REGN
Regeneron Pharmaceuticals Inc
$695.42
+0.03%
HEALTHCARE · Cap: $68.27B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 1383266% more annual revenue ($14.92B vs $1.08M). REGN leads profitability with a 29.6% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 64/100 (C+).
AUTL
Avoid31
out of 100
Grade: F
REGN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+56.1%
Fair Value
$3.26
Current Price
$1.46
$1.80 discount
Margin of Safety
+50.0%
Fair Value
$1334.57
Current Price
$695.42
$639.15 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 83655.0% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Weak financial health signals
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : AUTL
The strongest argument for AUTL centers on Price/Book, Revenue Growth. Revenue growth of 83655.0% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 29.6% and operating margin at 20.7%. Revenue growth of 19.0% demonstrates continued momentum.
Bear Case : AUTL
The primary concerns for AUTL are EPS Growth, Market Cap, Profit Margin.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
AUTL profiles as a hypergrowth stock while REGN is a growth play — different risk/reward profiles.
AUTL carries more volatility with a beta of 2.00 — expect wider price swings.
AUTL is growing revenue faster at 83655.0% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (64/100 vs 31/100), backed by strong 29.6% margins and 19.0% revenue growth. AUTL offers better value entry with a 56.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Autolus Therapeutics Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T-cell therapies for the treatment of cancer. The company is headquartered in London, the United Kingdom.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?